{
    "nctId": "NCT00301106",
    "briefTitle": "Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver",
    "officialTitle": "Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patients With Metastatic Breast Cancer to the Liver",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Metastatic Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2,
    "primaryOutcomeMeasure": "Toxicity",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed\\* breast adenocarcinoma metastatic to the liver\n\n  * Solitary or multiple hepatic metastases\n\n    * No malignant involvement of \\> 40% of the estimated liver volume NOTE: \\*Must be from the hepatic tumor designated for study injection\n* Metastatic liver tumors must be measurable in \u2265 2 dimensions on CT scan or MRI\n* At least 1 metastatic hepatic tumor \u2265 2 cm in diameter must be visualized by ultrasound and accessible for percutaneous injection under ultrasound guidance\n* Extrahepatic metastasis allowed\n* No solitary hepatic metastasis eligible for liver resection\n* No clinical evidence for severe liver disease (e.g., prior or current ascites or portosystemic encephalopathy)\n* Hormone-receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Menopausal status not specified\n* Granulocyte count \u2265 1,500/mm\\^3\n* Hemoglobin \u2265 9.0 g/dL\n* Platelet count \u2265 100,000/mm\\^3\n* PT \u2264 14.5 sec\n* Creatinine \u2264 1.5 mg/dL OR creatinine clearance \u2265 45 mL/min\n* Bilirubin \u2264 2 times upper limit of normal (ULN)\n* Transaminases \u2264 2.5 times ULN\n* Karnofsky performance status \u2265 70%\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for at least 2 months after completion of study treatment\n* No active infection or serious intercurrent medical illness\n* No HIV infection\n* Life expectancy \u2265 16 weeks\n* No other malignancy within the past 5 years except inactive nonmelanoma skin cancer, in situ carcinoma of the cervix, or grade 1 papillary bladder cancer\n* At highest dose level, patient must weigh \u2265 30 kg\n\nPRIOR CONCURRENT THERAPY:\n\n* No systemic immunosuppressive drugs, including corticosteroids, within 2 months prior to study entry\n\n  * Not require immunosuppressive drugs or anticoagulant therapy with heparin or warfarin for at least 2 months after study treatment\n* No chemotherapy within 4 weeks of study entry (6 weeks for nitrosoureas)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}